1-7 of 7
Sharyn Baker
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Preclinical Development of Hosu-53, a Novel Potent Dihydroorotate Dehydrogenase Inhibitor with Impressive Single Agent Efficacy and Combination Approaches in Hematological Malignancy

Erin Hertlein, Chad Bennett, Ola A Elgamal, Sandip Vibhute, Sharyn Baker, Thomas E Goodwin, Don M. Benson, Jr., Christopher Coss, Jeffrey Patrick, Gerald Hilinski, John C. Byrd
Journal: Blood
Blood (2022) 140 (Supplement 1): 10695–10696.
https://doi.org/10.1182/blood-2022-167671
Published: 2022
Journal Articles

Targeting the WT1 mut -M ir-193a Transcriptional Axis with INT-1B3, a Novel Lipid Nanoparticle-Formulated Mir -193a-3p Mimic in Acute Myeloid Leukemia

Xining Yang, Kathrin Krowiorz, Raj Bhayadia, Jessica Kohlschmidt, Deedra Nicolet, Tobias Maetzig, Caroline Pabst, Jeremy Hui, Arshia Shad, Sharon Gao, Maria Stephenson, Si Wei Wu, Marion van den Bosch, Daelynn Buelow, Sharyn Baker, Leo Escano, Frances E Lock, Afsaneh Panahi, Liam MacPhee, Irina Maksakova, Amanda Amoah, Konstanze Döhner, Linda Fogelstrand, Ann-Kathrin Eisfeld, Sanaz Yahyanejad, Michel Janicot, Christopher C. Oakes, Jan-Henning Klusmann, Arefeh Rouhi, Florian Kuchenbauer
Journal: Blood
Blood (2022) 140 (Supplement 1): 6224–6225.
https://doi.org/10.1182/blood-2022-157833
Published: 2022
Journal Articles

Molecular and Clinical Features of FLT3 Juxtamembrane Domain Point Mutations (muts) in Acute Myeloid Leukemia (AML)

Nadeen Anabtawi, Jessica Kohlschmidt, Daelynn Buelow, Shelley Orwick, Kennedy Coleman, Krzysztof Mrózek, Jonathan E. Kolitz, Bayard L. Powell, William G. Blum, Maria R. Baer, John C. Byrd, Wendy Stock, Geoffrey L. Uy, Ann-Kathrin Eisfeld, Sharyn Baker, James S. Blachly
Journal: Blood
Blood (2022) 140 (Supplement 1): 6244–6246.
https://doi.org/10.1182/blood-2022-171222
Published: 2022
Journal Articles

A Novel Inhibitor of FLT3 and Its Drug-Resistant Mutants with Superior Activity to Gilteritinib in Molm-13 Preclinical Acute Myeloid Leukemia Xenograft Model

Ola A Elgamal, James R Lerma, Allison Mullaney, Emily Stahl, Blaise Stearns, Andrew Orry, Polo Chun-Hung Lam, Ruben Abagyan, Alexei Pushechnikov, Nikolay Savchuk, Volodymyr Kysil, Hovhannes Gukasyan, Iain Dukes, Oleg Mitkin, Ruben Karapetian, Alexei Riakhovskii, Elena Bulanova, Vladislav Parchinsky, Alexandre Ivachtchenko, Sharyn Baker, Erin Hertlein, John C. Byrd
Journal: Blood
Blood (2022) 140 (Supplement 1): 3352–3353.
https://doi.org/10.1182/blood-2022-165675
Published: 2022
Journal Articles

High-Dimensional Analysis Identifies Mechanisms of Gilteritinib Resistance in FLT3 -Mutated AML

Daelynn R Buelow, Bhavana Bhatnagar, Jae Yoon Jeon, Megan Zavorka Thomas, Eric Eisenmann, Jack Stromatt, Shelley Orwick, Navjot Pabla, James S. Blachly, Sharyn Baker, Bradley W Blaser
Journal: Blood
Blood (2021) 138 (Supplement 1): 207.
https://doi.org/10.1182/blood-2021-148569
Published: 2021
Journal Articles

TP-0903, a Novel Axl Inhibitor with Activity in Drug Resistant FLT3-ITD+ AML through a Mechanism That Includes FLT3 Inhibition

Jae Yoon Jeon, PharmD, Il-Kyoo Park, PhD, Daelynn R Buelow, PhD, Clifford Whatcott, PhD, Steven L. Warner, PhD, William Blum, MD, Sharyn Baker, PharmD
Journal: Blood
Blood (2017) 130 (Supplement 1): 2522.
https://doi.org/10.1182/blood.V130.Suppl_1.2522.2522
Published: 2017
Journal Articles

Differentiation Therapy for Poor Risk Myeloid Malignancies: Results of a Dose Finding Study of Bryostatin-1 (BRYO) + GM-CSF.

B. Douglas Smith, MD, William H. Matsui, MD, Douglas E. Gladstone, MD, Judith E. Karp, MD, Steven D. Gore, MD, Carol Ann Huff, MD, Milada Vala, Sharyn Baker, MD, Ming Zhao, PhD, Steven Piantadosi, MD, Richard J. Jones, MD
Journal: Blood
Blood (2005) 106 (11): 2792.
https://doi.org/10.1182/blood.V106.11.2792.2792
Published: 2005